Addition of Abemaciclib to Aromatase Inhibitor Therapy Prolongs Survival in HR+/HER2- Breast Cancer
September 25th 2022For patients receiving an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer, the addition of abemaciclib doubled median progression-free survival vs placebo.